We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form” global category.
Cell therapies represent an exciting new treatment paradigm for patients, with multiple global approvals expected in the coming years. As with any new and emerging therapy, patient challenges and operating model complexities still require further optimization to improve accessibility.
Watch this on-demand webinar for insights on how working with a single integrated CRO/CDMO partner can help ease industry challenges and provide an accelerated path from development to manufacturing, as well as the benefits that come from unified teams and infrastructure.